Lactobacilli and pleuropulmonary infection

Serious infections due to lactobacilli have been rarely reported [1, 2]. The most common clinical syndromes are endocarditis and sepsis arising from localized infection. Recently we published the first case of pneumonia caused by Lactobacillus sp [3]. To date only two other cases of pleuropulmonary infection have been published [4]; an empyema and a pneumonia with a concomitant non-related lactobacillaemia.

After our first report we have seen two more cases of Lactobacillus empyema. The first case is a patient with a squamous carcinoma of the oesophagus, in whom the insertion of a prosthesis was the origin of a pleuroesophageal fistula that caused an empyema; culture of the pleural exudate yielded Lactobacillus sp and Bacteroides distasonis. The second case is a patient with hepatic cirrhosis who required surgical therapy for oesophageal variceal bleeding. After the surgical procedure a chest film showed a pleural effusion. Thoracentesis evidenced an empyema, and Lactobacillus sp and Pseudomonas aeruginosa were identified in the culture. In this patient the hypothetical pleuropulmonary fistula could not be proven with an oesophagogram.

The first case is very similar to the one we published recently [3]; here an oesophageal carcinoma was also the origin of the pleuropulmonary fistula. The fistula between the gastrointestinal tract and pleura or lung must exist for the establishment of infection by Lactobacillus sp.

Lactobacilli are usually sensitive to penicillin, ampicillin and co-trimoxazole [5, 6] but in two of our cases the strains were tolerant to clindamycin and co-trimoxazole and the third was tolerant to co-trimoxazole and tetracycline.

References

J. M. Querol Borras, F. Manresa,
F. Barbe, M. Cisnal*

Servei de Pneumologia
* Servei de Microbiologia
Hospital de Bellvitge
08907 L'hospitalet
Barcelona
Spain

The 1987 update of the 1962 and 1967 questionnaires (European Respiratory Journal 1989, 2, 165-177) is to be welcomed for the anomalies which have been sorted out and for not making any radical change, such as has damaged the 1986 MRC questionnaire [1]. However, there are several features which in our view should be restored; first, question 18 on wheeze. The new version does not distinguish between wheeze occasionally and on most days, yet this has proven most helpful in our studies of shipyard workers amongst whom the decrement of lung function associated with “wheeze occasionally” is, on average, about half that which accompanies wheeze on most days [2]. The circumstances in which wheeze usually occurs are also in our view informative,
as do the ATS which distinguishes between wheeze with colds and at other times [3]. Second, previous chest illness (question 26, d); this no longer contains a check list to remind the subject of illnesses which might otherwise be forgotten. In our experience, the failure to supply a list leads to the giving of false negative replies. This could be important because a history of pneumonia or pleurisy are both associated with some loss of lung function even in the absence of respiratory symptoms [2]. Third, smoking questions. The omission of the question on whether or not a person inhales is probably of no consequence for the average male cigarette smoker. It is important for female cigarette smokers and for cigar and pipe smokers; some persons in these categories inhale to the detriment of their chest whilst others do not and failure to make the distinction could restrict data analysis unnecessarily. An additional restriction is the failure to record the month and year, instead of age, at which an ex-smoker finally gave up. Without the additional information it is in some circumstances impossible to decide if a person is an ex-smoker according to an exact definition, or merely a short-term abstainer.

We believe these omissions detract from the usefulness of the questionnaire and very much hope they will be restored. This is particularly important if the use of the questionnaire is to be made mandatory for ECSC grant holders. We hope this will not be the case for circumstances where an alternative would be more appropriate.

References


J. E. Cotes, D. J. Chinn

School of Health Care Sciences
The Medical School
Framlington Place
Newcastle upon Tyne NE2 4HH

Epidermal growth factor receptors

Slebos and Rodenhuis in their excellent review of the molecular genetics of lung cancer (Eur Respir J, 1989, 2, 461–469) pointed out the need for information on the clinical behaviour of lung cancers expressing epidermal growth factor (EGF) receptors. We wish to draw to your attention our study [1] showing that immunoperoxidase staining with the R1 antibody to the EGF receptor is significantly stronger on lung tumours than normal lung tissue. Furthermore, we found that the staining in 40 squamous tumours was significantly stronger than for other non-small cell cancers and there was stronger staining in 30 stage 3 non-small cell lung cancers compared to 47 stage 1 and stage 2 tumours, as classified by the TNM classification. Since the stage of tumour at presentation is of prognostic significance, we feel that the degree of EGF receptor expression on non-small cell lung cancers may be of predictive value in these tumours.

References


D. Veale, G. J. Gibson

Freeman Hospital
Freeman Road
High Heaton
Newcastle upon Tyne
NE7 7DN

Corrigendum


Figures 2 and 3 were inadvertently transposed during printing. They should be reversed for correct order to match the legends.